While immunotherapy has been a growing field over the past twenty-five years, with the emergence of SARS-CoV-2, immunotherapies to combat the virus are now paramount. Advances in antibody therapies and vaccines will evolve more rapidly now than ever before, and will provide an abundant source of potentially valuable intellectual property rights. These IP rights and assets are typically one of the significant value drivers for such business transactions as mergers and acquisitions, joint collaborations and license transactions.
The unique nature of IP rights can create inadvertent legal traps that can jeopardize the value of the transaction by not allowing the parties to realize the full benefit of the IP they were hoping to acquire or exploit. During our presentation, we will discuss what life sciences companies need to watch out for and will offer practical steps to avoid these traps. Through a series of examples, they will reveal some of the most common traps in IP licensing and collaborations encountered by life sciences companies today.
Join Professor Yaakov “Koby” Nahmias of Hebrew University and Mayer Brown Partners Vera Nackovic and Lisa Ferri for a discussion on emerging issues at the intersection of immunotherapy and intellectual property.
We also invite you to read our Immuno-Innovation blog, reporting at the intersection of immunotherapy and intellectual property law with legal analysis, updates on case law and legislative developments, as well as trend-spotting and best practices.
CLE is not available when viewing a recording of this program. In order to receive credit you must have attended the live webinar program.